difference between crospovidone and sodium starch glycolate

Out of all the decisions a solid-dosage formulator makes, the choice between crospovidone and sodium starch glycolate is one that directly determines whether a tablet falls apart fast enough to release the active ingredient. The difference between crospovidone and sodium starch glycolate isn’t just a detail in the fine print of an excipient monograph. It shapes disintegration time, impact on hardness, moisture sensitivity, and performance under varying compression forces. Both are classified as superdisintegrants and appear in hundreds of OTC and prescription products worldwide. Yet their mechanisms, chemical structures, and behaviour inside a tablet matrix are fundamentally different. Choosing the wrong one can delay bioavailability or ruin a perfectly good direct-compression blend.

Most formulators have worked with both. Some will even tell you they’re interchangeable within the typical 1–5% use range. That oversimplification is dangerous. In wet-granulated paracetamol tablets, for instance, crospovidone can deliver a disintegration time under three minutes while an identical grade of sodium starch glycolate might push past six minutes. In high-pressure roller-compacted formulations, the gap widens further. Getting the decision right means understanding what each excipient actually does with water, how it interacts with your filler and API, and what happens as compression force climbs. That’s what this article unpacks — with data pulled from pharmacopoeias, published excipient monographs, and practical manufacturing experience.

Yuking, a Polyvinylpyrrolidone PVP Polymer Manufacturer product range that includes pharmaceutical-grade crospovidone, has fielded countless questions from customers weighing these two materials. The discussion below walks through mechanism, structural chemistry, a detailed performance comparison, and practical guidelines you can use at the bench.

Where the real difference begins: mechanism, not just speed

Superdisintegrants work fast, but they don’t all work the same way. Crospovidone relies predominantly on wicking and a unique shape-recovery property. The individual particles are highly porous, insoluble, cross-linked polyvinylpyrrolidone networks. When water contacts a particle, capillary action pulls liquid into the pores almost instantly. As the particle hydrates, it expands slightly — usually less than 30–50% in volume — but the real force comes from the elastic recovery of the particle structure after compression. Under the microscope, crospovidone particles behave like tiny sponges that were squashed during tableting and snap back to their original shape the moment liquid releases the stress.

Sodium starch glycolate follows a different playbook. It hydrates rapidly and swells to roughly 200–300% of its original volume. That swelling pressure physically pushes adjacent particles apart and breaks the tablet matrix. This mechanism is highly effective in many formulations, but it depends on unrestricted space. If the surrounding matrix is dense or contains hygroscopic materials that compete for water, the swelling force can drop off sharply. Tests under USP <701> conditions show that in a purely microcrystalline cellulose-based tablet compressed to 12 kN, 2% crospovidone can yield an average disintegration time of 25–45 seconds, while the same level of sodium starch glycolate may give 35–65 seconds — close, but the gap widens when filler hydrophobicity increases.

These two mechanisms don’t just affect speed; they affect robustness. Crospovidone’s wicking action works across a wide pH range and in purely aqueous or partially alcoholic media, while the swelling of sodium starch glycolate is sensitive to ionic strength and pH extremes. Formulators developing orally disintegrating tablets often lean toward crospovidone exactly because its non-swelling mechanism preserves the tablet’s mouthfeel and avoids the gummy sensation swelling can cause.

What structural chemistry tells you about behaviour in wet granulation and direct compression

Crospovidone is a cross-linked homopolymer of N-vinyl-2-pyrrolidone. The cross-linking, achieved typically through a popcorn polymerization process, renders the material completely insoluble in water and most organic solvents. The resulting popcorn-shaped particles have an internal surface area measured by BET nitrogen adsorption that can exceed 1.0 m²/g — sometimes approaching 1.5 m²/g for finer grades. That enormous surface area explains the rapid wicking. It also explains why crospovidone does not form a gel layer; water simply fills the pores without dissolving the polymer backbone. Manufacturers like Yuking supply crospovidone complying with USP-NF, Ph. Eur., and JP monographs, with typical particle size grades covering both fine (< 50 µm) and coarse (< 200 µm) cuts. A standard Yuking grade carries a loss on drying below 5.0% and a residue on ignition below 0.1%.

Sodium starch glycolate is the sodium salt of a cross-linked carboxymethyl ether of starch. The base polymer — amylopectin-rich starch — is esterified and lightly cross-linked. It swells because the ionized carboxyl groups draw water into the polymer chains, separating them dramatically without dissolving. The starch backbone brings some inherent biodegradability and a hydrophilic profile, but it also means the material can be more sensitive to formulation pH. In an acidic environment (pH 1–3), sodium starch glycolate’s swelling capacity drops measurably; some studies report a 30–40% reduction in swelling volume compared with neutral conditions. This pH sensitivity matters for APIs that are absorbed in the stomach: a tablet may disintegrate well in pH 4.5 buffer but underperform in 0.1 N HCl.

Particle morphology tells another part of the story. Crospovidone has an irregular, porous, cavern-like shape that resists plastic deformation. Under compression, particles lock together but do not form permanent bonds, which is why the elastic recovery kick can break them apart later. Sodium starch glycolate particles are somewhat smoother and more rounded, and they tend to deform plastically. A direct consequence: crospovidone usually preserves disintegration efficiency better than sodium starch glycolate at higher compression forces — say above 15 kN — especially in purely excipient compacts.

Side-by-side performance numbers: how the data lines up

Laboratories and monograph compilers have generated dozens of comparative datasets. Below is a summary table drawing on typical values reported in the Handbook of Pharmaceutical Excipients (8th edition), USP-NF reference materials, and manufacturer technical data sheets.

| Parameter | Crospovidone | Sodium Starch Glycolate | |-----------|--------------|-------------------------| | Appearance | White to off-white, free-flowing porous powder | White to off-white, free-flowing powder | | Typical D50 particle size | 100–150 µm (standard grade) | 40–70 µm (type A); 80–120 µm (type B) | | Bulk density | 0.20–0.30 g/mL | 0.40–0.55 g/mL | | Water uptake capacity | 4–6 g water per g polymer (wicking) | 15–20 g water per g polymer (swelling) | | Volume swelling ratio | 1.3–1.5× original volume | 2.0–3.0× original volume | | Disintegration time (2%, DCP/MCC tablet, 12 kN)* | 25–45 s | 35–65 s | | pH effect on disintegration | Minimal across pH 1–8 | Reduced efficiency below pH 3 | | Hygroscopicity | Low; equilibration to < 30% RH | Moderate; care needed >60% RH | | Typical use concentration | 1–5% | 2–8% (often higher for rapid disintegrant needs) |

*Values are indicative; actual performance depends on API, filler, lubrication, and processing.

Quantitative estimates from internal screening at several excipient manufacturers suggest that at 20 kN compression — typical for robust industrial tablets — crospovidone retains approximately 80–90% of its disintegration efficiency relative to 10 kN, while sodium starch glycolate may drop to 60–70%. Those percentages aren’t universal; they depend on filler ductility. But the pattern holds over enough formulations to be a reliable selection factor.

Another concrete data point comes from iodine adsorption capacity, a rough indicator of crospovidone’s surface area. USP-grade crospovidone typically shows an iodine number between 1.2 and 2.0 meq/g, corresponding to a high degree of porosity. Sodium starch glycolate has no direct equivalent, which doesn’t mean lower quality; it just underscores that different tests reveal different performance traits.

When to favour one over the other in real-world tablet design

Experienced formulators often develop a checklist based not on absolute superiority but on fit with the rest of the formulation. Use these comparison-driven heuristics to narrow your choice.

Prefer crospovidone when: - The formulation uses high compression forces (>15 kN) and you need consistent disintegration across a tight hardness range. - The API is hydrophobic (e.g., carbamazepine, ibuprofen) and wicking is needed to bring water into the compact. - You’re developing orally disintegrating tablets; crospovidone’s non-gelling, non-swelling action improves mouthfeel. - The product must perform reliably at low stomach pH, where sodium starch glycolate swelling wanes. - You need a superdisintegrant that works efficiently at low concentrations (1–2%).

Prefer sodium starch glycolate when: - The tablet matrix contains water-soluble fillers (lactose, sorbitol) that provide a natural aqueous pathway, and swelling complements the matrix dissolution. - Cost is a decisive factor at very high unit volumes; sodium starch glycolate can be less expensive on a per-kilogram basis for large commodity products. - The wet granulation process includes an aqueous binder step where starch-derived materials integrate well. - You need a disintegrant concentration window above 4%, where crospovidone’s effect can plateau, but sodium starch glycolate’s swelling continues to increase.

It’s also worth looking closely at how granulation method interacts with excipient. This analysis of the cross-linking mechanism behind crospovidone’s breakdown power details why crospovidone remains effective even when added intra-granularly before wetting, while sodium starch glycolate may lose some potency if over-wet and pre-swollen during granulation.

In one Yuking-supported customer project, a BCS class II API formulation initially relied on 5% sodium starch glycolate and failed to meet an in-house disintegration target of <5 min in 0.1 N HCl. Swapping in 3% crospovidone (a USP-grade product from Yuking’s portfolio) brought the disintegration time to 2.8 min without changing tablet hardness, and the dissolution Q30 value jumped from 72% to 94%. These numbers reflect a specific formulation, not a universal promise — a pilot trial is always necessary — but they illustrate the kind of step-change that mechanism-aligned selection can deliver.

Common mistakes that cost time and out-of-spec results

Even seasoned teams can trip over a few recurring errors when handling these two excipients. Watch for them.

Mistaking crospovidone for soluble povidone. Regular povidone dissolves in water to form a viscous binder. Crospovidone does not dissolve. If a formulator substitutes soluble PVP for crospovidone by mistake, the tablet won’t disintegrate; it will hydrate into a hard gel. Always verify the grade and confirm water insolubility before use. Understanding why crospovidone stays insoluble explains the cross-linking chemistry behind this durable insolubility.

Neglecting the impact of lubricant type and mixing time. Both crospovidone and sodium starch glycolate are porous. Magnesium stearate can coat these pores if blending occurs for too long or too intensely. A 15-minute over-blend with 1% magnesium stearate has been shown to increase disintegration time by 50–100% for sodium starch glycolate formulations and up to 30–40% for crospovidone. Keep lubricant blending to the minimum needed for uniform distribution.

Using the same disintegrant concentration regardless of final hardness. A tablet compressed to 8 kN and one compressed to 18 kN tell completely different stories. A level of 2% crospovidone that works beautifully at low pressure may need bumping to 3% at high pressure, but it will still outperform sodium starch glycolate that has been raised from 4% to 6% under the same conditions. Always map concentration vs. hardness; don’t assume linear scalability.

Storing sodium starch glycolate in high-humidity conditions without sealed containers. While both excipients are somewhat hygroscopic, sodium starch glycolate can absorb up to 20% moisture at 75% RH, leading to erratic disintegration and potential API degradation. Crospovidone equilibrates at about 15–18% moisture under the same conditions and usually causes fewer stability issues tied to moisture.

Frequently Asked Questions

Can crospovidone and sodium starch glycolate be used together in the same formulation?

Yes, a combined approach sometimes yields synergistic effects. For example, 1.5% crospovidone plus 2% sodium starch glycolate can provide both rapid initial wicking and sustained swelling, especially in tablets with microcrystalline cellulose and dicalcium phosphate. Pilot trials should verify that the combination does not lead to gelling or residue.

Which superdisintegrant works better in chewable tablets?

Crospovidone is generally preferred because it creates a clean-breaking tablet without a gummy mouthfeel. Sodium starch glycolate can impart a sticky, hydrating sensation that some consumers find unpleasant. The porous nature of crospovidone also aids in rapid breakdown upon chewing.

Does crospovidone have any impact on tablet hardness?

Crospovidone’s elastic nature can slightly reduce tensile strength at higher concentrations because it doesn’t bond permanently under compression. Compensate by adjusting compression force or adding a dry binder. The drop is usually small — within 5–10% of hardness at 3% disintegrant — but should be factored into robustness studies.

Are there regulatory differences between the two?

Both are recognized in all major pharmacopoeias (USP-NF, Ph. Eur., JP). Crospovidone is monographed as Crospovidone, and sodium starch glycolate as Sodium Starch Glycolate Type A and B. From a regulatory filing standpoint, they share DMF availability and are widely accepted in generic and NDA submissions.

Comparing crospovidone and sodium starch glycolate at the monograph level often convinces formulators that both will do the job. Real manufacturing tells a different story. The difference between crospovidone and sodium starch glycolate surfaces most clearly where moisture limits, pH conditions, and mechanical stress collide. Crospovidone thrives under high compaction forces and low pH by pulling water through a capillary network without relying on swelling. Sodium starch glycolate delivers reliable swelling-driven breakup when water is plentiful and the matrix offers room to expand. Selecting the right one isn’t about better or worse. It’s about mapping those physical mechanisms onto your specific API, filler, and process. Start with a small Design of Experiments spanning two concentrations and a hardness range. In a matter of days, you’ll have the data that no general guide can replace — and a formulation that disintegrates exactly when patients need it to.